Previous 10 | Next 10 |
– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO ® (bempedoic acid) Tablet and NUSTENDI ® (bempedoic acid and ezetimibe) Tablet – ȁ...
2024-01-02 10:00:00 ET Summary United Therapeutics Corporation calls itself a "Public Benefit" company. The reality, it is a cynical monopolist about to lose its monopoly. If patent trolling fails, their premium to the entrant could collapse. Disclaimer . ...
2023-12-18 12:22:29 ET DENVER, Colo., Dec. 18, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Invivyd Inc (NASDAQ: IVVD), ZimVie Inc (NASDAQ: ZIMV), Panbela Therapeutics Inc (NASDAQ: PBLA), Esperi...
ANN ARBOR, Mich., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 42 nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO, will deliver a corporate presentation on Wednesday, January 10, 2024, at 2:15 PM PT (5:15 PM ...
2023-12-14 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Ocular Therape...
2023-12-14 09:57:42 ET DENVER, Colo., Dec. 14, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Freight Technologies Inc (NASDAQ: FRGT), ZyVersa Therapeutics Inc (NASDAQ: ZVSA), Esperion Therapeutics Inc (...
2023-12-13 16:27:44 ET More on Esperion Therapeutics Esperion: Navigating The 'Bemp' Of Success Amidst Market Waves And Legal Tides Esperion Therapeutics, Inc. (ESPR) Q3 2023 Earnings Call Transcript Esperion Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Prese...
– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – – Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of March 31; in Europe with Anticipated Approval in 1H 2024 ...
2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...
– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation – ȁ...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...